Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All sotrovimab studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchSotrovimabSotrovimab (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

Effectiveness of the neutralizing antibody sotrovimab among high-risk patients with mild-to-moderate SARS-CoV-2 in Qatar

Zaqout et al., International Journal of Infectious Diseases, doi:10.1016/j.ijid.2022.09.023 (date from preprint)
Apr 2022  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
0 0.5 1 1.5 2+ Progression -165% Improvement Relative Risk Sotrovimab  Zaqout et al.  EARLY TREATMENT Is early treatment with sotrovimab beneficial for COVID-19? Retrospective 928 patients in Qatar (October 2021 - February 2022) Higher progression with sotrovimab (not stat. sig., p=0.19) c19early.org Zaqout et al., Int. J. Infectious Dise.., Apr 2022 Favors sotrovimab Favors control
Sotrovimab for COVID-19
40th treatment shown to reduce risk in May 2023
 
*, now known with p = 0.0017 from 22 studies, recognized in 38 countries. Efficacy is variant dependent.
Lower risk for hospitalization.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
4,200+ studies for 70+ treatments. c19early.org
Retrospective 345 sotrovimab treated patients in Qatar matched with 583 patients that opted not to receive treatment, showing higher progression with treatment, without statistical significance.
Efficacy is variant dependent. In Vitro studies predict lower efficacy for BA.11-3, BA.4, BA.54, XBB.1.9.3, XBB.1.5.24, XBB.2.9, CH.1.15, and no efficacy for BA.26, ХВВ.1.9.1, XBB.1.16, BQ.1.1.45, and CL.15. US EUA has been revoked.
risk of progression, 164.7% higher, RR 2.65, p = 0.19, treatment 4 of 345 (1.2%), control 3 of 583 (0.5%), adjusted per study, odds ratio converted to relative risk, progression to severe/critical disease or mortality.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Zaqout et al., 21 Apr 2022, retrospective, Qatar, peer-reviewed, median age 40.0, 17 authors, study period 20 October, 2021 - 28 February, 2022. Contact: azaqout@hamad.qa, lja2002@qatarmed.cornell.edu.
This PaperSotrovimabAll
Effectiveness of the neutralizing antibody sotrovimab among high-risk patients with mild-to-moderate SARS-CoV-2 in Qatar
Dr Ahmed Zaqout, Muna A Almaslamani, Hiam Chemaitelly, Samar A Hashim, Ajithkumar Ittaman, Abeir Alimam, Fatma Rustom, Joanne Daghfal, Mohammed Abukhattab, Sawsan Almukdad, Anvar Hassan Kaleeckal, Ali Nizar Latif, Adeel A Butt, Roberto Bertollini, Abdullatif Al-Khal, Ali S Omrani, Laith J Abu-Raddad
International Journal of Infectious Diseases, doi:10.1016/j.ijid.2022.09.023
Objectives: To estimate the real-world effectiveness of sotrovimab against severe, critical, or fatal COVID-19 in Qatar at a time in which most SARS-CoV-2 incidences occurred due to the BA.2 Omicron subvariant. Methods: We conducted a matched case-control study among all individuals eligible for sotrovimab treatment per United States Food and Drug Administration guidelines in the resident population of Qatar. The odds of progression to severe forms of COVID-19 were compared in cases (treatment group) versus controls (eligible patients who opted not to receive the treatment). Subgroup analyses were conducted. Results: A total of 3364 individuals were eligible for sotrovimab treatment during the study period, of whom 519 individuals received the treatment, whereas the remaining 2845 constituted the controls. The adjusted odds ratio of disease progression to severe, critical, or fatal COVID-19 comparing the treatment group to the control group was 2.67 (95% confidence interval 0.60-11.91). In the analysis including only the subgroup of patients at higher risk of severe forms of COVID-19, the adjusted odds ratio was 0.65 (95% confidence interval 0.17-2.48). Conclusion: There was no evidence for a protective effect of sotrovimab in reducing COVID-19 severity in a setting dominated by the BA.2 subvariant.
Funding The authors are grateful for institutional salary support from Hamad Medical Corporation, the Ministry of Public Health, and the Biomedical Research Program and the Biostatistics, Epidemiology, and Biomathematics Research Core, both at Weill Cornell Medicine-Qatar. The authors are also grateful to the Qatar Genome Programme and Qatar University Biomedical Research Center for institutional support for the reagents needed for the viral genome sequencing. The funders of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the article. Statements made herein are solely the responsibility of the authors. Ethical approval The Hamad Medical Corporation and Weill Cornell Medicine-Qatar Institutional Review Boards approved this retrospective study with a waiver of informed consent. The research was performed in accordance with relevant guidelines and regulations. Author contributions AZ, MAA, and ASO co-designed the study, led the database development, and co-wrote the manuscript. HC co-designed the study, performed the statistical analyses, and co-wrote the first draft of the article. LJA co-designed the study, led the statistical analyses, and co-wrote the first draft of the article. All authors contributed to data collection and acquisition, database development, discussion and interpretation of the results, and the writing of the manuscript. All authors have read and approved the final manuscript. Declaration of..
References
Abu-Raddad, Chemaitelly, Ayoub, Almukdad, Yassine et al., Effect of mRNA vaccine boosters against SARS-CoV-2 omicron infection in Qatar, N Engl J Med
Abu-Raddad, Chemaitelly, Ayoub, Kanaani, Khal et al., Characterizing the Qatar advanced-phase SARS-CoV-2 epidemic, Sci Rep
Abu-Raddad, Chemaitelly, Coyle, Malek, Ahmed et al., SARS-CoV-2 antibody-positivity protects against reinfection for at least seven months with 95% efficacy, EClinicalmedicine
Aggarwal, Beaty, Bennett, Carlson, Davis et al., Realworld evidence of the neutralizing monoclonal antibody sotrovimab for preventing hospitalization and mortality in COVID-19 outpatients, J Infect Dis, doi:10.1093/infdis/jiac206
Altarawneh, Chemaitelly, Ayoub, Tang, Hasan et al., Effects of previous infection and vaccination on symptomatic omicron infections, N Engl J Med
Austin, Using the standardized difference to compare the prevalence of a binary variable between two groups in observational research, Commun Stat Simul Comput
Butt, Dargham, Loka, Shaik, Chemaitelly et al., COVID-19 Disease Severity in Children Infected with the Omicron Variant, Clin Infect Dis 2022a, doi:10.1093/cid/ciac275
Butt, Dargham, Tang, Chemaitelly, Hasan et al., COVID-19 disease severity in persons infected with the Omicron variant compared with the Delta variant in Qatar, J Glob Health
Chemaitelly, Ayoub, Almukdad, Coyle, Tang et al., Duration of mRNA vaccine protection against SARS-CoV-2 Omicron BA.1 and BA.2 subvariants in Qatar, Nat Commun 2022b
Chemaitelly, Ayoub, Coyle, Tang, Yassine et al., Protection of Omicron sub-lineage infection against reinfection with another Omicron sub-lineage, Nat Commun 2022a
Chemaitelly, Tang, Hasan, Almukdad, Yassine et al., Waning of BNT162b2 vaccine protection against SARS-CoV-2 infection in Qatar, N Engl J Med
Feikin, Abu-Raddad, Andrews, Davies, Higdon et al., Assessing vaccine effectiveness against severe COVID-19 disease caused by omicron variant. Report from a meeting of the World Health Organization, Vaccine
Gupta, Gonzalez-Rojas, Juarez, Casal, Moya et al., Early treatment for Covid-19 with SARS-CoV-2 neutralizing antibody sotrovimab, N Engl J Med
Gupta, Gonzalez-Rojas, Juarez, Casal, Moya et al., Effect of sotrovimab on hospitalization or death among high-risk patients with mild to moderate COVID-19: a randomized clinical trial, JAMA
Huang, Mccreary, Bariola, Minnier, Wadas et al., Effectiveness of casirivimab-imdevimab and sotrovimab during a SARS-CoV-2 Delta variant surge: a cohort study and randomized comparative effectiveness trial, JAMA Netw Open, doi:10.1001/jamanetworkopen.2022.20957
Kojima, Shrestha, Klausner, A systematic review of the protective effect of prior SARS-CoV-2 infection on repeat infection, Eval Health Prof
Miguez-Rey, Choi, Kim, Yoon, Monoclonal antibody therapies in the management of SARS-CoV-2 infection, Expert Opin Investig Drugs
Ong, Ren, Lee, Sutjipto, Dugan et al., Real-world use of sotrovimab for pre-emptive treatment in high-risk hospitalized COVID-19 patients: an observational cross-sectional study, Antibiotics
Stowe, Andrews, Kirsebom, Ramsay, Bernal, Effectiveness of COVID-19 vaccines against Omicron and Delta hospitalisation, a test negative case-control study, Nat Comm, doi:10.1038/s41467-022-33378-7
Takashita, Kinoshita, Yamayoshi, Sakai-Tagawa, Fujisaki et al., Efficacy of Antiviral Agents against the SARS-CoV-2 Omicron Subvariant BA.2, N Engl J Med 2022b, doi:10.1056/NEJMc2201933
Takashita, Kinoshita, Yamayoshi, Sakai-Tagawa, Fujisaki et al., Efficacy of antibodies and antiviral drugs against Covid-19 omicron variant, N Engl J Med 2022a
{ 'indexed': { 'date-parts': [[2022, 10, 11]], 'date-time': '2022-10-11T22:44:18Z', 'timestamp': 1665528258404}, 'reference-count': 24, 'publisher': 'Elsevier BV', 'license': [ { 'start': { 'date-parts': [[2022, 11, 1]], 'date-time': '2022-11-01T00:00:00Z', 'timestamp': 1667260800000}, 'content-version': 'tdm', 'delay-in-days': 0, 'URL': 'https://www.elsevier.com/tdm/userlicense/1.0/'}, { 'start': { 'date-parts': [[2022, 9, 14]], 'date-time': '2022-09-14T00:00:00Z', 'timestamp': 1663113600000}, 'content-version': 'vor', 'delay-in-days': 0, 'URL': 'http://creativecommons.org/licenses/by/4.0/'}], 'content-domain': { 'domain': [ 'clinicalkey.fr', 'clinicalkey.jp', 'clinicalkey.es', 'clinicalkey.com.au', 'clinicalkey.com', 'ijidonline.com', 'elsevier.com', 'sciencedirect.com'], 'crossmark-restriction': True}, 'published-print': {'date-parts': [[2022, 11]]}, 'DOI': '10.1016/j.ijid.2022.09.023', 'type': 'journal-article', 'created': {'date-parts': [[2022, 9, 19]], 'date-time': '2022-09-19T16:07:00Z', 'timestamp': 1663603620000}, 'page': '96-103', 'update-policy': 'http://dx.doi.org/10.1016/elsevier_cm_policy', 'source': 'Crossref', 'is-referenced-by-count': 0, 'title': 'Effectiveness of the neutralizing antibody sotrovimab among high-risk patients with ' 'mild-to-moderate SARS-CoV-2 in Qatar', 'prefix': '10.1016', 'volume': '124', 'author': [ { 'ORCID': 'http://orcid.org/0000-0002-0173-9697', 'authenticated-orcid': False, 'given': 'Ahmed', 'family': 'Zaqout', 'sequence': 'first', 'affiliation': []}, {'given': 'Muna A.', 'family': 'Almaslamani', 'sequence': 'additional', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0000-0002-8756-6968', 'authenticated-orcid': False, 'given': 'Hiam', 'family': 'Chemaitelly', 'sequence': 'additional', 'affiliation': []}, {'given': 'Samar A.', 'family': 'Hashim', 'sequence': 'additional', 'affiliation': []}, {'given': 'Ajithkumar', 'family': 'Ittaman', 'sequence': 'additional', 'affiliation': []}, {'given': 'Abeir', 'family': 'Alimam', 'sequence': 'additional', 'affiliation': []}, {'given': 'Fatma', 'family': 'Rustom', 'sequence': 'additional', 'affiliation': []}, {'given': 'Joanne', 'family': 'Daghfal', 'sequence': 'additional', 'affiliation': []}, {'given': 'Mohammed', 'family': 'Abukhattab', 'sequence': 'additional', 'affiliation': []}, {'given': 'Sawsan', 'family': 'AlMukdad', 'sequence': 'additional', 'affiliation': []}, {'given': 'Anvar Hassan', 'family': 'Kaleeckal', 'sequence': 'additional', 'affiliation': []}, {'given': 'Ali Nizar', 'family': 'Latif', 'sequence': 'additional', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0000-0002-1118-1826', 'authenticated-orcid': False, 'given': 'Adeel A.', 'family': 'Butt', 'sequence': 'additional', 'affiliation': []}, {'given': 'Roberto', 'family': 'Bertollini', 'sequence': 'additional', 'affiliation': []}, {'given': 'Abdullatif', 'family': 'Al-Khal', 'sequence': 'additional', 'affiliation': []}, {'given': 'Ali S.', 'family': 'Omrani', 'sequence': 'additional', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0000-0003-0790-0506', 'authenticated-orcid': False, 'given': 'Laith J.', 'family': 'Abu-Raddad', 'sequence': 'additional', 'affiliation': []}], 'member': '78', 'reference': [ { 'key': '10.1016/j.ijid.2022.09.023_bib0001', 'doi-asserted-by': 'crossref', 'first-page': '6233', 'DOI': '10.1038/s41598-021-85428-7', 'article-title': 'Characterizing the Qatar advanced-phase SARS-CoV-2 epidemic', 'volume': '11', 'author': 'Abu-Raddad', 'year': '2021', 'journal-title': 'Sci Rep'}, { 'key': '10.1016/j.ijid.2022.09.023_bib0002', 'doi-asserted-by': 'crossref', 'DOI': '10.1016/j.eclinm.2021.100861', 'article-title': 'SARS-CoV-2 antibody-positivity protects against reinfection for at ' 'least seven months with 95% efficacy', 'volume': '35', 'author': 'Abu-Raddad', 'year': '2021', 'journal-title': 'EClinicalmedicine'}, { 'key': '10.1016/j.ijid.2022.09.023_bib0003', 'doi-asserted-by': 'crossref', 'first-page': '1804', 'DOI': '10.1056/NEJMoa2200797', 'article-title': 'Effect of mRNA vaccine boosters against SARS-CoV-2 omicron infection in ' 'Qatar', 'volume': '386', 'author': 'Abu-Raddad', 'year': '2022', 'journal-title': 'N Engl J Med'}, { 'key': '10.1016/j.ijid.2022.09.023_bib0020', 'doi-asserted-by': 'crossref', 'first-page': '995', 'DOI': '10.1056/NEJMc2119407', 'article-title': 'Efficacy of antibodies and antiviral drugs against Covid-19 omicron ' 'variant', 'volume': '386', 'author': 'Takashita', 'year': '2022', 'journal-title': 'N Engl J Med'}, { 'key': '10.1016/j.ijid.2022.09.023_bib24', 'doi-asserted-by': 'crossref', 'first-page': '1475', 'DOI': '10.1056/NEJMc2201933', 'article-title': 'Efficacy of Antiviral Agents against the SARS-CoV-2 Omicron Subvariant ' 'BA.2', 'volume': '386', 'author': 'Takashita', 'year': '2022', 'journal-title': 'N Engl J Med'}, { 'key': '10.1016/j.ijid.2022.09.023_bib0004', 'doi-asserted-by': 'crossref', 'first-page': '622', 'DOI': '10.1016/S1473-3099(21)00751-9', 'article-title': 'Efficacy and safety of two neutralising monoclonal antibody therapies, ' 'sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with ' 'COVID-19 (TICO): a randomised controlled trial', 'volume': '22', 'year': '2022', 'journal-title': 'Lancet Infect Dis'}, { 'key': '10.1016/j.ijid.2022.09.023_bib0005', 'doi-asserted-by': 'crossref', 'article-title': 'Real-world evidence of the neutralizing monoclonal antibody sotrovimab ' 'for preventing hospitalization and mortality in COVID-19 outpatients', 'author': 'Aggarwal', 'year': '2022', 'journal-title': 'J Infect Dis', 'DOI': '10.1093/infdis/jiac206'}, { 'key': '10.1016/j.ijid.2022.09.023_bib0006', 'doi-asserted-by': 'crossref', 'first-page': '21', 'DOI': '10.1056/NEJMoa2203965', 'article-title': 'Effects of previous infection and vaccination on symptomatic omicron ' 'infections', 'volume': '387', 'author': 'Altarawneh', 'year': '2022', 'journal-title': 'N Engl J Med'}, { 'key': '10.1016/j.ijid.2022.09.023_bib0007', 'doi-asserted-by': 'crossref', 'first-page': '1228', 'DOI': '10.1080/03610910902859574', 'article-title': 'Using the standardized difference to compare the prevalence of a binary ' 'variable between two groups in observational research', 'volume': '38', 'author': 'Austin', 'year': '2009', 'journal-title': 'Commun Stat Simul Comput'}, { 'issue': '1', 'key': '10.1016/j.ijid.2022.09.023_bib23', 'doi-asserted-by': 'crossref', 'first-page': 'e361', 'DOI': '10.1093/cid/ciac275', 'article-title': 'COVID-19 Disease Severity in Children Infected with the Omicron Variant', 'volume': '75', 'author': 'Butt', 'year': '2022', 'journal-title': 'Clin Infect Dis'}, { 'key': '10.1016/j.ijid.2022.09.023_bib0008', 'doi-asserted-by': 'crossref', 'first-page': '05032', 'DOI': '10.7189/jogh.12.05032', 'article-title': 'COVID-19 disease severity in persons infected with the Omicron variant ' 'compared with the Delta variant in Qatar', 'volume': '12', 'author': 'Butt', 'year': '2022', 'journal-title': 'J Glob Health'}, { 'key': '10.1016/j.ijid.2022.09.023_bib0009', 'doi-asserted-by': 'crossref', 'first-page': 'e83', 'DOI': '10.1056/NEJMoa2114114', 'article-title': 'Waning of BNT162b2 vaccine protection against SARS-CoV-2 infection in ' 'Qatar', 'volume': '385', 'author': 'Chemaitelly', 'year': '2021', 'journal-title': 'N Engl J Med'}, { 'key': '10.1016/j.ijid.2022.09.023_bib0010', 'doi-asserted-by': 'crossref', 'first-page': '4675', 'DOI': '10.1038/s41467-022-32363-4', 'article-title': 'Protection of Omicron sub-lineage infection against reinfection with ' 'another Omicron sub-lineage', 'volume': '13', 'author': 'Chemaitelly', 'year': '2022', 'journal-title': 'Nat Commun'}, { 'key': '10.1016/j.ijid.2022.09.023_bib0011', 'doi-asserted-by': 'crossref', 'first-page': '3082', 'DOI': '10.1038/s41467-022-30895-3', 'article-title': 'Duration of mRNA vaccine protection against SARS-CoV-2 Omicron BA.1 and ' 'BA.2 subvariants in Qatar', 'volume': '13', 'author': 'Chemaitelly', 'year': '2022', 'journal-title': 'Nat Commun'}, { 'key': '10.1016/j.ijid.2022.09.023_bib0012', 'doi-asserted-by': 'crossref', 'first-page': '3516', 'DOI': '10.1016/j.vaccine.2022.04.069', 'article-title': 'Assessing vaccine effectiveness against severe COVID-19 disease caused ' 'by omicron variant. Report from a meeting of the World Health ' 'Organization', 'volume': '40', 'author': 'Feikin', 'year': '2022', 'journal-title': 'Vaccine'}, { 'key': '10.1016/j.ijid.2022.09.023_bib0013', 'doi-asserted-by': 'crossref', 'first-page': '1941', 'DOI': '10.1056/NEJMoa2107934', 'article-title': 'Early treatment for Covid-19 with SARS-CoV-2 neutralizing antibody ' 'sotrovimab', 'volume': '385', 'author': 'Gupta', 'year': '2021', 'journal-title': 'N Engl J Med'}, { 'key': '10.1016/j.ijid.2022.09.023_bib0014', 'doi-asserted-by': 'crossref', 'first-page': '1236', 'DOI': '10.1001/jama.2022.2832', 'article-title': 'Effect of sotrovimab on hospitalization or death among high-risk ' 'patients with mild to moderate COVID-19: a randomized clinical trial', 'volume': '327', 'author': 'Gupta', 'year': '2022', 'journal-title': 'JAMA'}, { 'issue': '7', 'key': '10.1016/j.ijid.2022.09.023_bib0015', 'doi-asserted-by': 'crossref', 'DOI': '10.1001/jamanetworkopen.2022.20957', 'article-title': 'Effectiveness of casirivimab-imdevimab and sotrovimab during a ' 'SARS-CoV-2 Delta variant surge: a cohort study and randomized ' 'comparative effectiveness trial', 'volume': '5', 'author': 'Huang', 'year': '2022', 'journal-title': 'JAMA Netw Open'}, { 'key': '10.1016/j.ijid.2022.09.023_bib0016', 'doi-asserted-by': 'crossref', 'first-page': '327', 'DOI': '10.1177/01632787211047932', 'article-title': 'A systematic review of the protective effect of prior SARS-CoV-2 ' 'infection on repeat infection', 'volume': '44', 'author': 'Kojima', 'year': '2021', 'journal-title': 'Eval Health Prof'}, { 'key': '10.1016/j.ijid.2022.09.023_bib0017', 'doi-asserted-by': 'crossref', 'first-page': '41', 'DOI': '10.1080/13543784.2022.2030310', 'article-title': 'Monoclonal antibody therapies in the management of SARS-CoV-2 infection', 'volume': '31', 'author': 'Miguez-Rey', 'year': '2022', 'journal-title': 'Expert Opin Investig Drugs'}, { 'key': '10.1016/j.ijid.2022.09.023_bib0018', 'doi-asserted-by': 'crossref', 'first-page': '345', 'DOI': '10.3390/antibiotics11030345', 'article-title': 'Real-world use of sotrovimab for pre-emptive treatment in high-risk ' 'hospitalized COVID-19 patients: an observational cross-sectional study', 'volume': '11', 'author': 'Ong', 'year': '2022', 'journal-title': 'Antibiotics (Basel)'}, { 'key': '10.1016/j.ijid.2022.09.023_bib0019', 'doi-asserted-by': 'crossref', 'first-page': '5736', 'DOI': '10.1038/s41467-022-33378-7', 'article-title': 'Effectiveness of COVID-19 vaccines against Omicron and Delta ' 'hospitalisation, a test negative case-control study', 'volume': '13', 'author': 'Stowe', 'year': '2022', 'journal-title': 'Nat Comm'}, { 'key': '10.1016/j.ijid.2022.09.023_bib0021', 'series-title': 'Emergency use authorization (EUA) of sotrovimab, 2022', 'year': '2022'}, { 'key': '10.1016/j.ijid.2022.09.023_bib0022', 'unstructured': 'World Health Organization. International guidelines for certification ' 'and classification (coding) of COVID-19 as cause of death. 2020. ' 'Available at: ' 'https://www.who.int/publications/m/item/international-guidelines-for-certification-and-classification-(coding)-of-covid-19-as-cause-of-death. ' 'Accessed May 31, 2021.'}], 'container-title': 'International Journal of Infectious Diseases', 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'https://api.elsevier.com/content/article/PII:S1201971222005227?httpAccept=text/xml', 'content-type': 'text/xml', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://api.elsevier.com/content/article/PII:S1201971222005227?httpAccept=text/plain', 'content-type': 'text/plain', 'content-version': 'vor', 'intended-application': 'text-mining'}], 'deposited': { 'date-parts': [[2022, 10, 11]], 'date-time': '2022-10-11T22:19:03Z', 'timestamp': 1665526743000}, 'score': 1, 'resource': {'primary': {'URL': 'https://linkinghub.elsevier.com/retrieve/pii/S1201971222005227'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2022, 11]]}, 'references-count': 24, 'alternative-id': ['S1201971222005227'], 'URL': 'http://dx.doi.org/10.1016/j.ijid.2022.09.023', 'relation': {}, 'ISSN': ['1201-9712'], 'subject': ['Infectious Diseases', 'Microbiology (medical)', 'General Medicine'], 'container-title-short': 'International Journal of Infectious Diseases', 'published': {'date-parts': [[2022, 11]]}, 'assertion': [ {'value': 'Elsevier', 'name': 'publisher', 'label': 'This article is maintained by'}, { 'value': 'Effectiveness of the neutralizing antibody sotrovimab among high-risk patients ' 'with mild-to-moderate SARS-CoV-2 in Qatar', 'name': 'articletitle', 'label': 'Article Title'}, { 'value': 'International Journal of Infectious Diseases', 'name': 'journaltitle', 'label': 'Journal Title'}, { 'value': 'https://doi.org/10.1016/j.ijid.2022.09.023', 'name': 'articlelink', 'label': 'CrossRef DOI link to publisher maintained version'}, {'value': 'article', 'name': 'content_type', 'label': 'Content Type'}, { 'value': '© 2022 The Author(s). Published by Elsevier Ltd on behalf of International ' 'Society for Infectious Diseases.', 'name': 'copyright', 'label': 'Copyright'}]}
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit